Merck & Co., Inc. (ETR: 6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 271.14B |
| Revenue (ttm) | 58.31B |
| Net Income (ttm) | 12.82B |
| Shares Out | n/a |
| EPS (ttm) | 5.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Sep 16, 2024 |
| Volume | 688 |
| Open | 104.40 |
| Previous Close | 107.60 |
| Day's Range | 104.40 - 108.40 |
| 52-Week Range | 91.00 - 125.60 |
| Beta | 0.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 31, 2024 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv... [Read more]
Financial Performance
In 2023, NCB's revenue was $94.19 billion, an increase of 1.93% compared to the previous year's $92.41 billion. Earnings were $24.87 billion, a decrease of -4.42%.
Financial numbers in USD Financial StatementsNews
Eighty-eight Corporate Leaders Endorse Harris For Continued 'Strength' Of Democracy, Economy
Letter signers include Yelp, Snap and Box CEOs, media empire heir James Murdoch, former CEOs of PepsiCo, Lyft and Merck
Why Did Merck Stock Rise 65%?
Merck stock (NYSE: MRK) has gained over 65% in value since early January 2021 – jumping from levels of $70 then to around $115 now – vs. an increase of about 50% for the S&P 500 over this period.
What's Going On With Merck Shares Thursday?
Merck stock is trading higher on ... Full story available on Benzinga.com
What's Wrong With Merck's Stock?
Is the healthcare stock an underrated buy right now?
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and six pipeline candidates in more than 20 types of cancer will be p...
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and six pipeline candida...
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret for the Treatment of Diabetic Macular Edema
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway, N.J., USA, today announced the initiation of the Phase 2b/3...
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway, N.J., USA, today announced t...
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Merck & Co. (NYSE: MRK) and Gilead Sciences Inc. (NYSE: GILD) are two pharmaceutical heavyweights whose stocks tell very different stories . Rahway, New Jersey-based Merck just flashed a Death Cross...
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.
Updating Walmart, Merck And Nike Post-Earnings
Walmart’s probably the best of the three in terms of catalysts for further P/E and cash-flow expansion over the next 12 – 15 months, suggests the author. Click to read.
Updating Walmart, Merck And Nike Post-Earnings
Walmart’s probably the best of the three in terms of catalysts for further P/E and cash-flow expansion over the next 12 – 15 months, suggests the author. Click to read.
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Over the weekend, the U.S. government announced first-ever negotiated prices for prescription drugs for ten drugs covered under Medicare Part D that will go into effect beginning January 1, 2026 . The...
Amid Major Threats, Merck Stock Is A Sell
Amid Major Threats, Merck Stock Is A Sell
(MRK) - Analyzing Merck & Co's Short Interest
Merck & Co's (NYSE: MRK) short percent of float has risen 8.25% since its last report. The company recently reported that it has 26.72 million shares sold short , which is 1.05% of all regular shares...
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Tuesday, Vaxcyte, Inc. (NASDAQ: PCVX) released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the company's 31-valent pneumococcal conjugat...
Merck’s Keytruda with Pfizer’s Padcev approved in EU for first-line bladder cancer
Merck (MRK) wins EU approval for Keytruda as first-line therapy for bladder cancer in combination with Pfizer (PFE) and Astellas' (ALPMY) Padcev. Read more here.
Merck’s Keytruda with Pfizer’s Padcev approved in EU for first-line bladder cancer
Merck (MRK) wins EU approval for Keytruda as first-line therapy for bladder cancer in combination with Pfizer (PFE) and Astellas' (ALPMY) Padcev. Read more here.
European Commission Approves Merck’s KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combinat...
European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA + EV EC Approval.
Merck's Change To Profit Guidance Provides An Opportunity
Merck's Change To Profit Guidance Provides An Opportunity
Behind the Scenes of Merck & Co's Latest Options Trends
Investors with a lot of money to spend have taken a bearish stance on Merck & Co (NYSE: MRK). And retail traders should know. We noticed this today when the positions showed up on publicly available ...
Merck scraps two late-stage trials of cancer drug Keytruda
Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial failures for the b...